Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Reaffirms Their Hold Rating on Novartis AG (NOVN)

Tipranks - Tipranks - Sun Mar 22, 9:58AM CDT

Barclays analyst James Gordon CFA maintained a Hold rating on Novartis AG yesterday and set a price target of CHF120.00. The company’s shares closed yesterday at CHF115.60.

Claim 70% Off TipRanks Premium

Gordon CFA covers the Healthcare sector, focusing on stocks such as Novo Nordisk, GlaxoSmithKline, and Galderma Group AG. According to TipRanks, Gordon CFA has an average return of 5.3% and a 48.28% success rate on recommended stocks.

In addition to Barclays, Novartis AG also received a Hold from Berenberg Bank’s Luisa Hector in a report issued on March 6. However, yesterday, Goldman Sachs maintained a Sell rating on Novartis AG (Six Swiss: NOVN).

See the top stocks recommended by analysts >>

Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion

Read More on CH:NOVN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).